The drug patent link system has been implemented in our country with the implementation of the new Patent Law of China on June 1st, 2021 and the implementation of “Early Resolution Mechanism for Drug Patent Disputes” on July 4th. To ensure the successful implementation of the patent link system, this paper analyzes the key elements of early resolution mechanism for drug patent disputes with Chinese characteristics, based on a comparative study of the overall framework of the drug patent link system in the United States, South Korea and Canada, combined with the development status and legislation of China's pharmaceutical industry at this stage. On the basis of the above, according to the reality of pharmaceutical industry, the characteristics of judicial and administrative systems in our country, this paper explores the early resolution mechanism for drug patent disputes suitable for China's national conditions under the framework principles established by the new Patent Law.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |